Celularity Inc

GX Acquisition Corp (Nasdaq: GXGX) is a blank check company that completed its initial public offering in 2019, with its search focused on the healthcare and life sciences sector. The SPAC later announced and completed a business combination with Celularity Inc., a clinical-stage biotechnology company developing allogeneic cell therapies sourced from the human placenta. The August 2019 Form 10-Q, filed under GX Acquisition Corp, captures the company during its pre-combination phase as a special purpose acquisition vehicle. Celularity, founded by Robert Hariri, targets oncology and infectious disease applications through placental-derived cellular medicines. Sign up at SpacDesk for complete filing history, deal timelines, and SPAC analytics on GXGX.